Trials / Recruiting
RecruitingNCT05360290
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 484 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | GILUPI CellCollector® | Use of GILUPI CellCollector® to detect CTC |
Timeline
- Start date
- 2022-09-14
- Primary completion
- 2026-06-01
- Completion
- 2029-06-01
- First posted
- 2022-05-04
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05360290. Inclusion in this directory is not an endorsement.